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ABSTRACT
Diabetes is currently affecting 30 million Americans. To combat disease onset, lifestyle
interventions have been focused on. Low water intake, alongside elevated concentrations of
circulating copeptin, has been linked to increased risk for. However, it is unknown whether this
effect on glucose regulation is acute or chronic. Furthermore, no study to date assessed the
effects of copeptin independent of the renin-angiotensin-aldosterone system (RAAS). Purpose:
The purpose of these studies was therefore two-fold: 1) to establish high endogenous copeptin
concentrations independent of RAAS, and 2) to assess glucose metabolism following a
standardized oral glucose tolerance test (OGTT) during high concentrations of c copeptin.
Methods: 60 subjects participated in this randomized, crossover design study. On two trial days,
subjects were infused for 120-min with either 0.9 % sodium chloride (NaCl, ISO) or 3.0 % NaCl
(HYPER) (Study 1). Post infusion, a 240-min oral glucose tolerance test (OGTT, 75 g) was
administered (Study 2). Changes in plasma volume (∆PV), plasma osmolality (POsm),
electrolyte, copeptin, glucose, insulin, glucagon, crh, acth and cortisol concentrations were
measured every 30 min. Results: During HYPER, plasma osmolality (POsm) and copeptin
increased (P<0.05) and remained elevated during the entire six-hour protocol, while RAAS
hormones were within the lower normal physiological range at baseline, and declined following
infusion. Fasting plasma glucose did not differ between trials (P >0.05) at baseline and during
the 120-min of infusion. During the OGTT the positive integer of the area under the curve
(AUC) for glucose was greater during HYPER (401.5±190.5 mmol·L-1·min) vs. the ISO trial
(354.0±205.8 mmol·L-1·min, P< 0.05). The positive integer of the AUC for insulin during
OGTT did not differ between trials (HYPER: 55,850±36,488 vs. ISO: 57,205±31,119 pmol·L1·min).

Baseline values of serum glucagon were not different between the two trials, however,

the AUC of glucagon during the OGTT was also significantly greater in HYPER (19,303±3,939
ng·L-1·min) vs. the ISO trial (18,600±3,755 ng·L-1·min; P < 0.05). Conclusion: The present data
indicate that acute osmotic stimulation of copeptin induced greater hyperglycemic responses
during the oral glucose challenge possibly due to greater glucagon levels.
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I.
INTRODUCTION
The global burden of diabetes is increasing at alarming rates. Whereas in 2010, 285
million people were reported as diabetic, this number has reached an estimated 415 million in
merely 5 years (1). The Center for Disease Control and Prevention estimates, that, following
current trends, as many as 1 in 3 American adults could suffer from diabetes by 2050 (2). This
rampant rise in prevalence urgently calls for a change in programs and policies targeting
awareness, improving diagnosis and identification of additional risk factors for T2DM with the
ultimate goal to contain this major health crisis (3).
Risk factors for diabetes are categorized as non-modifiable and potentially modifiable
factors. With age, family history/genetic predisposition, ethnicity, a history of gestational
diabetes (GDM), and polycystic ovary syndrome being considered non-modifiable, it is the
modifiable category that allows for intervention and delay of T2DM onset in at-risk populations
(4, 5). So far, the most important potentially modifiable risk factors for T2DM have been
identified as sedentary lifestyle, poor dietary habits, and sleep deprivation (6). In clinical trial
settings, lifestyle interventions targeting reduction in central obesity (7) via changes in diet and
increased physical activity, have shown efficacy in combating the pathophysiological cascade
leading to T2DM with outcomes exceeding those resulting from pharmaceutical approaches (8,
9). While we seem to have identified efficacious methodologies improve modifiable risk factors
such as reducing central obesity via increase in physical activity and improved nutrition, barriers
such as poor motivation; lack of time; environmental, societal and social pressures;
socioeconomic constraints; along with health and physical limitations prevent these
methodologies to be adapted successfully in free living adults, outside of the clinical trial setting
1

(10). Therefore, the search for additional, potentially more easily modified risk factors must
continue.
Recently, epidemiological studies have associated low water intake with increased risk
for new-onset hyperglycemia (11); while overall higher plain water intake has been associated
with lower overall T2DM risk (12) and lower glycated hemoglobin (HbA1C) values in males
(13). During states of low water intake, an imbalance of fluid gain to fluid loss results in an
increase in plasma osmolality (POsm) which stimulates the release of arginine vasopressin (AVP)
from the posterior pituitary (14). Via activation of AVP specific V2 receptors, aquaporin
channels at level of the kidney open and reabsorption of water into the vasculature is facilitated
(15, 16). Furthermore, AVP has been shown to elicit hyperglycemic effects in rat and mouse
models, presumably via hepatic glucose production (17, 18). Inconsistent findings in regards to
AVP specific receptor involvement and signaling hierarchy during glucose and lipid metabolism
however, has deemed further investigations into pharmacological approaches to AVP receptor
antagonist/blocking therapy not yet feasible (19-22).
Lack of investigation of potential hyperglycemic effects of AVP in humans is likely
explained by the very short half-life of ~24min. However, in 2008, the group around Nils
Morgenthaler discovered the c-terminal peptide of 39-amino acids, copeptin, to be cleaving off
the same neurophysin II moieties as AVP and therefore being co-secreted from the posterior
pituitary (23, 24). Copeptin has since been shown to be more stable than AVP, while showing
similar responses to water intake and deprivation, terming it a valid surrogate marker (25).
Studies from European cohorts have since defined copeptin as a biomarker for T2DM risk in
European cohorts (26, 27).
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To our knowledge, only three human intervention trials to date have assessed the effect of
acute water intake interventions on lowering circulating copeptin and fasting glucose
concentrations (28-30), showing efficacy in those participants with habitually elevated copeptin
concentrations alone. However, only one study to date has assessed glycemic responses
following an acute elevation of copeptin concentrations. Interestingly, findings from this study
show no effect on glycemia (31).
While these studies are the first human interventional studies addressing this topic, no
methodology has been able to single out the potential interplay of circulating copeptin
concentrations on glucose metabolism as suggested by animal models.
The aim of the following investigation was therefore 2-fold: a) to utilize a method of
dehydration, which will allow for an acute rise in copeptin concentrations compared to control
independently of renin-angiotensin-II-aldosterone-system (RAAS) activation; b) to assess
glucose metabolism responses to a standardized oral glucose tolerance test during states of high
circulating copeptin concentrations compared to control while controlling for RAAS activity in
both conditions.
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II.
STUDY 1:
THE EFFECTS OF HYPERTONIC SALINE INFUSION ON INDEPENDENT
STIMULATION OF COPEPTIN

ABSTRACT
Background: While epidemiological studies have shown positive associations between the AVP
surrogate marker copeptin and risk for Type 2 diabetes mellitus (T2DM), early interventional
trials have yielded mixed results, which may be due to perturbations elicited by reninangiotensin-II-aldosterone-system (RAAS) activation.
Objective: To achieve RAAS-independent stimulation of AVP measured via surrogate marker
copeptin.
Design: 60 subjects (30 females) participated in this cross-over design study. On two trial days,
separated by at least seven days (males) or one menstrual cycle (females), subjects were infused
for 120-min with either 0.9 % sodium chloride (NaCl, ISO) or 3.0 % NaCl (HYPER).
Results: During HYPER, plasma osmolality (POsm) and copeptin increased (P<0.05) and
remained elevated during the entire two-hour protocol, while renin-angiotensin-aldosterone
system (RAAS) hormones were within the lower normal physiological range at the beginning of
the protocol and declined following infusion.
Conclusions: The present data indicate that acute osmotic stimulation via hypertonic saline
infusion results in stimulation of copeptin while reducing circulating RAAS hormone
concentrations. This method may be the preferred methodology to assess independent effects of
copeptin concentration on metabolic processes.
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This study was registered at ClinicalTrials.gov as NCT02761434.
Keywords: vasopressin; OGTT; dehydration; hydration; diabetes
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INTRODUCTION
Recent literature has linked low water intake and elevated concentrations of copeptin, a
surrogate marker of the fluid regulatory hormone arginine vasopressin with increased risk of new
onset hyperglycemia and an increased risk for type 2 diabetes mellitus (1-5). While analysis of
epidemiological data has found associations that support the hypothesis of prescribed hydration
practices as a preventative measure for the development of impaired glucose intolerance (1, 6),
results reported from interventional trials are mixed. These varying findings in interventional
trials are likely due to differing methodologies.
Studies investigating the efficacy of chronic changes in hydration practices assessed the
effect of increased water intake for interventions of 6 weeks (7) and 1 week (8) in healthy adults.
While the 6-week intervention prescribed 2 L·day-1 for men and 1.5 L·day-1 for women to
match the EFSA dietary reference values for fluid intake, the 1-week intervention trial included 3
L of water in addition to habitual fluid intake. Findings however differed, as that the 6-week
intervention reported a reduction in circulating copeptin concentrations in individual with low to
moderate total fluid intake, while the 1-week intervention, despite a higher water intervention
protocol, reported a response for individuals with habitually low water intake only.
In a follow-up study enrolling habitual low-drinkers with circulating copeptin
concentrations of 10.7 pmol·L-1 for males and 6.1 pmol·L-1 for females identified via a
population-based survey, Enhorning et al. reported a significant reduction in fasting plasma
glucose and copeptin concentrations following a 6-week 1.5 L·day-1(9). These findings, while
reporting a beneficial effect of increased water intake on fasting glucose and copeptin levels, also
underline that these effects are solely seen in individuals with elevated circulating copeptin
concentrations (2).
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Studies investigating the effect on glycemic responses following acute manipulation of
copeptin concentrations are few and stand in contrast to findings from the chronic intervention
protocols. Administering a model of acute hypohydration to assess its effect on glycemic
regulation in healthy adults, Carroll et al. utilized a passive heating protocol with subsequent
24-h fluid restriction to stimulate increased circulating concentrations of AVP, measured via
surrogate copeptin. When comparing oral glucose tolerance test (OGTT) responses to the fluid
replenished control trial however, no effect on glycemic regulation was detected. The lack of
findings could be due to trial design: the passive heating protocol administered to induce
hypohydration. Passive heating per se has previously been reported to affect glucose and insulin
concentrations (10). Further, aldosterone, another fluid regulatory hormone sensitive to plasma
volume losses as they occur during, for instance, passive heating, has been linked to decreased
insulin sensitivity in normal and obese individuals (11). Therefore, utilization of the passive
heating protocol could have caused perturbations, ultimately resulting in null-findings.
Johnson et al. tested the effect of a 3-day fluid restriction and hypothesized upregulation
of the renin-angiotensin-II-aldosterone-system (RAAS) and hypothalamic pituitary hormones on
glycemic responses in type 2 diabetics. While not measuring concentrations of copeptin, the
assessed impaired glucose tolerance to OGTT was attributed to elevated concentrations of
cortisol alone. With previous studies assessing acute effects of hypohydration while relying on
methodologies resulting in hypovolemic dehydration and subsequent stimulation of all fluid
regulatory pathways (12), we propose that the hypervolemic dehydration approach should be
utilized to allow for focus on the effect of copeptin on metabolic processes alone.
Hypertonic saline infusion protocols have been widely used to induce an osmotic
stimulus by raising plasma osmolality to study metabolic processes in a simulated dehydrated
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state (13-16). The infusion protocol with a hypertonic solution allows for an acute rise in POsm
and hence AVP stimulation that can be achieved within hours, without the inconvenience of
tedious water restriction protocols that place stress on the participant and often yield in noncompliance due to discomfort caused by symptoms of under-hydration such as intense thirst, dry
mouth, headache and impaired cognitive performance (17-20).
With intravenous fluid administration, volume loading occurs. Since RAAS is more
sensitive to activation of unloaded baroreceptors during states of decreased blood volume (21),
infusion protocols should therefore silence RAAS activity. Utilization of hypertonic solution
results in an increase in POsm dependent upon the solute load of the solution and duration, with
subjects considered to be entering hypertonicity at POsm values ≥300 (22). With induction of
hypertonicity, an increase in osmotic pressure gradient originating from the extracellular fluid
compartment will draw fluid from the inter-, and intracellular fluid compartments and a cellular
dehydration effect alongside a stimulation of arginine vasopressin release has been described
(23, 24) in efforts to reach osmotic equilibrium.
The aim of this study was therefore to induce hypertonic or isotonic states via intravenous
infusion, while assessing cellular dehydration via proxy measurements of plasma volume
expansion, total plasma protein and plasma potassium concentration, respectively. As a
secondary aim, this study sought to assess the effect of utilizing hypervolemic hypernatremia as
a means to suppress fluid regulatory hormones attributed to RAAS, while keeping AVP
stimulation, measured via surrogate marker copeptin, active.
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METHODS
Subjects
Out of 77 volunteers recruited between April 2016 and March 2017, 12 candidates failed
to meet inclusion criteria, while 5 subjects voluntarily withdrew from the study after enrollment.
Sixty adult volunteers (30 females) participated in this study [age, 39.0±8.0 y; weight, 78.2±15.2
kg; height, 1.70±0.09 m; BMI, 26.9±4.0 kg∙m-2]. The Consolidated Standards of Reporting
Trials (CONSORT) flow diagram is shown in Supplemental Figure 1.
During the screening process, subjects were required to complete a medical history
questionnaire which was reviewed by an advanced nurse practitioner to exclude patients with
diabetes, kidney disease, metabolic disorders, cardiovascular disease, and other potential fluid
balance covariates such as habitual use of non-steroidal anti-inflammatory drugs or serotonin
reuptake inhibitors. For female participants, the oral hormonal contraception method was
permitted as long as it included a seven-day wash-out period during their monthly cycle.
Pregnancy, lactation, or use of injectable contraceptives however, were additional exclusionary
factors. All participants signed an informed consent statement prior to enrollment. The study was
approved by the institutional review board for human experimentation in accordance with the
Helsinki Declaration of 1975 as revised in 1983. This trial was registered before the onset of
subject recruitment at www.clinicialtrials.gov as NCT02761434.

Experimental Design
In this counter-balanced, cross-over, and single-blind design study, each participant
completed two separate trials. To determine the acute effect of hypertonic saline infusion on
induction of cellular dehydration and hypertonic hypervolemia, participants received a 120-min
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saline infusion (Figure 1). Both trials differed only in saline concentration administered during
the infusion, with each subject receiving 0.1 ml∙kg-1∙min-1 of either hypertonic saline (HYPER,
3% NaCl), to raise POsm, thereby generating a transmembrane osmotic gradient, or isotonic
saline (ISO; 0.9% NaCl), to serve as control (15).

Study controls
Experimental days were separated by one week for males and post-menopausal or
ovariectomized females to ensure sufficient wash-out (16). Female subjects with regular
menstrual cycle were tested during the early follicular phase of two consecutive menstrual
cycles, to control for the effect of reproductive hormones on body fluid balance (25). For the 24h prior to testing subjects recorded all food and fluid intake into a provided food diary and
refrained from exercise, caffeine, and alcohol. In preparation for the second experimental day,
subjects received a copy of their first pre-trial dietary record and were asked to replicate it. To
standardize the dinner prior to each testing day, subjects consumed a provided frozen meal (two
Smart Ones Spaghetti bowls; 506 kcal, 78 g carbohydrates, 10 g fat, 26 g protein), before
entering a 10-h fasting period prior to the scheduled trial. During this 10-h fast, subjects were
allowed to drink plain water only. Lastly, to ensure adequate hydration, subjects were instructed
to consume provided bottled water based on the 80% of the Institute of Medicine reference
values for water intake (2 L for females and 3 L for males) for the day prior to each experiment
(26). These pre-trial hydration guidelines were based on data from the National Health and
Nutrition Examination Survey, which reports fluid intake to account for approximately 80% of
total water intake (27).
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Study protocol
All subjects reported to the lab following a 10-h fast and provided a urine sample.
Hydration status was assessed via urine specific gravity measurement with values <1.020
required to proceed with the protocol (28). Subjects then sat in a cushioned phlebotomy chair
(Convalescent Recliner – XL 5291, Winco Mfg., LLC, Ocala, FL, USA) and were not allowed to
stand-up or lay down until the end of the experiment to avoid intercompartmental body fluid
shifts associated with changes in body posture (29). An intravenous (IV) catheter was placed into
an antecubital vein and subjects rested for at least 20 min prior to baseline blood sampling.
Following the baseline blood sample collection, saline was infused via an IV pump (Baxter FloGuard® 6201, Baxter Healthcare Corporation, Deerfield, IL, USA) for 120 min, at a constant
rate of 0.1 ml∙kg-1∙min-1. Throughout the IV infusion (120 min), blood samples were taken
every 30 min for a total of 5 samples.

Biochemical analysis
At each timepoint, blood samples were analyzed for POsm (freezing point depression),
plasma sodium (PNa) concentration, plasma potassium (PK) concentration (ion-sensitive
electrodes), and total plasma protein (TPP) concentration (refractometry). Plasma volume
changes (∆PV) were calculated based on hematocrit and hemoglobin concentration via the Dill
& Costill equation (30). Copeptin was measured with random access immunoanalysis
(BRAHMS Kryptor Compact Plus, ThermoFisher, Berlin, Germany). Aldosterone and plasma
renin activity (PRA) were assessed by liquid chromatography/tandem mass spectrometry, while
angiotensin II (AII) concentrations were determined via radioimmunoassay.
Sample-size calculation
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Sample-size calculation was based on pilot data based on four subjects. To detect a difference of
≥3% in POsm, a total study sample of 11 participants would be required to test the null
hypothesis with a power of 0.8 and associated type 1 error rate  of 0.05.

Statistical analysis
Data were analyzed via repeated measures analysis of variance to assess within subject
responses across conditions, time, and condition by time. Baseline data were assessed for
normality via the Shapiro-Wilk test; with Bonferroni correction used as post-hoc. All data are
reported as means  standard deviation unless otherwise noted. Statistical significance was set a
priori at an  of 0.05. Statistical analysis was performed utilizing the software package JMP®
Pro 14.1 (SAS Institute Inc. 2018, Cary, NC, USA).

RESULTS
Baseline (pre-infusion)
The pre-programmed infusion volume did not differ between conditions within subjects
(938±183 mL), at a rate of 0.1 ml·kg -1·min-1. POsm, PNa, PK, TPP as well as the fluid regulatory
hormones copeptin, angiotensin II, aldosterone and plasma renin activity at the onset of the
infusion (0 min) did not differ between trials (P>0.05).

Manipulation of Tonicity
Administration of saline infusion yielded increased PNa and POsm values from baseline
for both conditions, respectively (Figure 1, Panel A & B; P < 0.05). Starting at 30min however,
hypertonic saline infusion resulted in significantly higher measured concentrations of PNa and
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POsm compared to isotonic control. These significantly higher POsm and PNa concentrations
remained elevated for the remainder of the infusion protocol.

Plasma Volume Expansion
Calculated percent changes in plasma volume (∆PV) were greater during HYPER
compared to ISO starting at 30min (Figure 2, Panel A; P < 0.05). In line, beginning at 30min,
measured total plasma protein showed significantly lower concentrations during HYPER.

Inorganic Ions
Presence of plasma chloride (PCl) increased from baseline during both conditions.
However, 30min into HYPER, PCl concentrations were significantly higher than during ISO,
with higher PCl concentrations measured during the remainder of HYPER compared to control
(Figure 3, Panel A, P < 0.05).
Plasma potassium (PK) concentrations also increased from baseline for both conditions,
with significantly higher PK concentration measured at the end of HYPER compared to the end
of ISO (Figure 3, Panel B, P < 0.05).

Fluid Regulatory Hormones
Plasma Renin Activity, aldosterone and angiotensin II were assessed at baseline and postinfusion 120min. Aldosterone showed a significant decline from baseline following both
conditions (Figure 4, Panel B, P < 0.05), while plasma renin activity and angiotensin II showed
a significant suppression following HYPER only (Figure 4, Panel A&C, P < 0.05).
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Copeptin concentrations increased from baseline starting at 60min for HYPER, while
maintaining baseline concentrations during ISO (Figure 4, Panel D, P < 0.05).

DISCUSSION
The purpose of this study was to assess the effect of hypertonic saline infusion on
induction of cellular dehydration with comparison of fluid regulatory hormone responses as a
secondary outcome. Saline infusion administration of either 3.0% (HYPER) or 0.9% (ISO)
resulted in hypertonic and isotonic Posm values, respectively.
When assessing indices of cellular dehydration, PK concentrations serve as a strong
indicator of presence of cellular water (31). Since cell membranes do not generate and maintain
significant hydrostatic pressure gradients, cell volume can only be regulated via gain or loss of
osmotically active solutes primarily via the inorganic ions Na+, K+ and Cl-, as well as small
organic osmolytes which yield cellular water efflux or influx (31, 32). As the major intracellular
inorganic cation, K+ exits the cell via activated K+ channels and K-CL cotransporters during
regulatory cellular volume decrease (33). Though extracellular osmolality and therefore
presumably intracellular osmotic pressure gradients were increased from baseline during both
experimental conditions, as measured via POsm, HYPER resulted in significantly higher POsm
values. In turn, this could explain the higher PK concentration measured after 120min of
hypernatremia, since no K+ was infused, unlike Na+ and Cl- respectively, the rise in inorganic K+
could therefore be interpreted as an indicator of cellular water efflux along the osmotic pressure
gradient.
Furthermore, calculations of percent changes in plasma volume (30), along with
measurements of total plasma protein concentration depict a heightened percent change in
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plasma volume, alongside a larger dilution of plasma protein content. Keeping in mind that
infusion boluses administered for both conditions were identical within subjects, we argue that
this is a further indication for fluid from the intra-and intercellular compartment entering the
extracellular vasculature along the acutely generated transmembrane osmotic gradient, ultimately
resulting in cellular shrinkage/dehydration(34-36).
The secondary aim of this study was to show a successful suppression of fluid regulatory
hormones involved with RAAS (37), while maintaining arginine vasopressin activity (38),
measured via the surrogate marker copeptin(39). RAAS affiliated hormones plasma renin
activity, angiotensin II and aldosterone all showed a significant suppression in concentration
from baseline following HYPER. This is likely explained due to the heightened percent change
in plasma volume, indicating hypervolemia. Expansion of blood volume results in the loading
and therefore silencing of baroreceptors specific to activation of aldosterone and the plasma
renin activity-angiotensin II cascade (21, 40). Copeptin concentrations on the other hand,
measured as a surrogate for arginine vasopressin, rose in response to the rise in POsm. Though
also responsive to losses in blood volume, arginine vasopressin release is highly sensitive to
changes in POsm; which yield in an activation of osmoreceptors in the hypothalamus and
ultimately result in the pituitary release of arginine vasopressin. With the utilization of a 120min
infusion of hypertonic saline we therefore show a suppression of RAAS activity, while not
interfering with the osmosensitive action of arginine vasopressin.
Our study comes with limitations. Hypertonic hypervolemia was achieved via acute
changes in extracellular osmolality and was therefore an anisosmotic stimulus placed on the
participant. This demands caution when interpreting the findings, as naturally occurring
dehydration is most likely isosomotic and more gradual, yielding in regulatory cell volume
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changes different from those reported here. Further, due to limitations in laboratory
instrumentation as well as the in vivo nature of the study, we were not able to directly measure
changes in cellular volume. Methodologies for assessment include ion-sensitive microelectrode,
as well as radioactive tracer methods, none of which were feasible within our current laboratory
setting. However, upon studying of the current literature we are confident that the proxy
procedures used to assess cellular fluid shifts as well as establishing an acute model of
dehydration are adequate.
In conclusion, administration of a 120-min bolus of 3.0% NaCl infusion resulted in acute
hypertonic hypervolemia. Cellular dehydration was likely achieved, marked by a significant rise
in PK at the end of infusion compared to isotonic control. Utilization of hypertonic saline
infusion was successful in suppressing RAAS while not interfering with osmotic activation of
arginine vasopressin release measured via surrogate marker copeptin.
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FIGURE LEGENDS
Figure 1.1
Protocol schematic. Abbreviations: NaCl, sodium chloride infusion.
Figure 1.2
Panel A: Measured plasma sodium (PNa) concentrations during administration of 0.9% and 3.0%
NaCl. Panel B: Measured plasma osmolality (POsm) during administration of 0.9% and 3.0%
NaCl. Levels not connected by the same letter are significantly different at P < 0.05. Data are
mean ± SE.
Figure 1.3
Panel A: Measured percent change in plasma volume (∆PV) during administration of 0.9% and
3.0% NaCl. Panel B: Measured total plasma protein (TPP) during administration of 0.9% and
3.0% NaCl. Levels not connected by the same letter are significantly different at P < 0.05. Data
are mean ± SE.
Figure 1.4
Panel A: Measured plasma potassium (PK) concentration during administration of 0.9% and
3.0% NaCl. Panel B: Measured plasma chloride (PCl) during administration of 0.9% and 3.0%
NaCl. Levels not connected by the same letter are significantly different at P < 0.05. Data are
mean ± SE.
Figure 1.5
Panel A: Measured plasma renin activity during administration of 0.9% and 3.0% NaCl. Panel B:
Measured aldosterone concentration during administration of 0.9% and 3.0% NaCl. Panel C:
Measured angiotensin II concentration during administration of 0.9% and 3.0% NaCl. Panel D:
Measured copeptin concentration during administration of 0.9% and 3.0% NaCl. Levels not
connected by the same letter are significantly different at P < 0.05. Data are mean ± SE.
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III.
STUDY 2:
OSMOTIC STIMULATION OF COPEPTIN ACUTELY IMPAIRS GLUCOSE REGULATION

ABSTRACT
Background: Epidemiological studies in humans show increased levels of copeptin, a surrogate
marker of arginine vasopressin (AVP), to be associated with increased risk for type 2 diabetes
(T2D).
Objective: To examine the acute and independent effect of osmotically stimulated AVP,
measured via the surrogate marker copeptin, on glucose regulation in healthy adults.
Design: 60 subjects (30 females) participated in this cross-over design study. On two trial days,
separated by at least seven days (males) or one menstrual cycle (females), subjects were infused
for 120-min with either 0.9 % sodium chloride (NaCl, ISO) or 3.0 % NaCl (HYPER). Post
infusion, a 240-min oral glucose tolerance test (OGTT, 75 g) was administered.
Results: During HYPER, plasma osmolality (POsm) and copeptin increased (P<0.05) and
remained elevated during the entire six-hour protocol, while renin-angiotensin-aldosterone
system (RAAS) hormones were within the lower normal physiological range at the beginning of
the protocol and declined following infusion. Fasting plasma glucose did not differ between trials
(P >0.05) at baseline and during the 120-min of infusion. During the OGTT the positive integer
of the area under the curve (AUC) for glucose was greater during HYPER (401.5±190.5
mmol·L-1·min) vs. the ISO trial (354.0±205.8 mmol·L-1·min, P< 0.05). The positive integer of
the AUC for insulin during OGTT did not differ between trials (HYPER: 55,850±36,488 vs.
ISO: 57,205±31,119 pmol·L-1·min). Baseline values of serum glucagon were not different
between the two trials, however, the AUC of glucagon during the OGTT was also significantly
30

greater in HYPER (19,303±3,939 ng·L-1·min) vs. the ISO trial (18,600±3,755 ng·L-1·min; P <
0.05).
Conclusions: The present data indicate that acute osmotic stimulation of copeptin induced
greater hyperglycemic responses during the oral glucose challenge possibly due to greater
glucagon levels.
This study was registered at ClinicalTrials.gov as NCT02761434.
Keywords: vasopressin; OGTT; dehydration; hydration; diabetes
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INTRODUCTION
Prevalence of chronic metabolic dysfunction is dramatically increasing worldwide and
has become both a major public health issue and a global economic burden (1). Impaired glucose
regulation is the hallmark for metabolic dysfunction; that could eventually lead to diabetes and
associated comorbidities. Most recent reports from the World Health Organization indicate that
the global number of people with diabetes has risen from 108 million in 1980 to 422 million in
2014, representing 8.5% of adults (2). In the United States alone, an estimated 84.1 million
people (33.9% of adults) had pre-diabetes in 2015 (3). While genetic make-up, age and sex have
been defined as non-modifiable risk factors for new onset of type 2 diabetes mellitus (T2D),
population-based studies revealed increased diabetes incidence occurring in parallel with major
and rapid changes in lifestyle behaviors (4). Therefore, there is an increasing and urgent need to
identify modifiable risk factors that may represent potential levers for the prevention of the onset
of metabolic dysfunctions and that may help to blunt the T2D epidemic. In addition to the major
modifiable contributors to this disease such as obesity, poor diet, and physical inactivity (5),
recent evidence suggests that the hormone AVP may be another key modifiable risk factor in the
development of diabetes (6-8).
AVP, also known as antidiuretic hormone, is the key hormone in the regulation of body
fluid balance; with one of its functions being the maintenance of plasma osmolality within a
narrow range. However, stimulation of AVP secretion, for instance in conditions of low water
intake, appears to be a risk factor for the development of diabetes (9). Indeed, preclinical studies
involving vasopressin injection, water intake manipulation, and the use of a vasopressin V1a
receptor-specific blockade, have collectively demonstrated that vasopressin and hydration play a
significant role on basal glycemia, glucose tolerance and liver steatosis in Zucker rats (10, 11).
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Similarly, research in mice lacking the V1b vasopressin receptor has shown to improve
insulin sensitivity (12).
Nonetheless, given the instability and low concentration of AVP in blood, the
measurement of copeptin, the stable C-terminal cleavage product of the vasopressin precursor
secreted in equimolar amounts with AVP, has become a surrogate and widely used proxy of
AVP secretion (13, 14). This has facilitated the measurement of antidiuretic activity in largescale population studies in which direct measurement of AVP would be unfeasible, and has
provided compelling epidemiological evidence linking copeptin, as a surrogate of AVP, to
metabolic health outcomes. Evidence from prospective population studies in multiple countries
report a strong, independent association of copeptin with hyperglycemia, higher risk of
developing T2D, diabetic cardiomyopathy, impaired insulin sensitivity and even death (6, 7, 15,
16). These findings have been further supported by a mendelian randomization approach
showing that at least in men, allelic variants increasing AVP (copeptin) concentration also appear
to increase incidence of impaired fasting glucose (17).
Yet, in humans, short-term studies designed to test the underlying mechanisms for AVP,
and metabolic dysfunction remain scarce. Furthermore, many pathways, including the secretion
of AVP, the Hypothalamic-Pituitary-Adrenal (HPA) axis, and the Renin-AngiotensinAldosterone System (RAAS), are interrelated (18-20) and are implicated with dysregulation of
glucose homeostasis (21-23). Additionally, certain traditional experimental methods of
increasing AVP via dehydration (exercise or exposure to heat) may have independent effects on
glucose homeostasis. Thus, the independent role of elevated AVP on glycemic control in human
remains unclear.
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Therefore, the aim of the present study was to examine the acute and independent effect
of osmotically stimulated AVP, measured via the surrogate marker copeptin, on glucose
regulation in healthy adults. An intravenous infusion protocol of hypertonic saline was employed
to osmotically stimulate AVP; while suppressing RAAS system via plasma volume expansion
and hypernatremia. We hypothesized that acute osmotic stimulation of AVP secretion, measured
via the surrogate marker copeptin, would lead to greater hyperglycemia during an oral glucose
tolerance test.

METHODS
Subjects
Out of 77 volunteers recruited between April 2016 and March 2017, 12 candidates failed
to meet inclusion criteria, while 5 subjects voluntarily withdrew from the study after enrollment.
Sixty adult volunteers (30 females) participated in this study [age, 39.0±8.0 y; weight, 78.2±15.2
kg; height, 1.70±0.09 m; BMI, 26.9±4.0 kg∙m-2; glycosylated hemoglobin (HbA1c), 5.2±0.3%].
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in
Supplemental Figure 1.
During the screening process, subjects were required to complete a medical history
questionnaire which was reviewed by an advanced nurse practitioner to exclude patients with
diabetes, kidney disease, metabolic disorders, cardiovascular disease, and other potential fluid
balance covariates such as habitual use of non-steroidal anti-inflammatory drugs or serotonin
reuptake inhibitors. To avoid enrollment of subjects with undiagnosed diabetes, HbA1c was
measured from capillary blood. For female participants, the oral hormonal contraception method
was permitted as long as it included a seven-day wash-out period during their monthly cycle.
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Pregnancy, lactation, or use of injectable contraceptives however, were additional exclusionary
factors. All participants signed an informed consent statement prior to enrollment. The study was
approved by the institutional review board for human experimentation in accordance with the
Helsinki Declaration of 1975 as revised in 1983. This trial was registered before the onset of
subject recruitment at www.clinicialtrials.gov as NCT02761434.

Experimental design
In this counter-balanced, cross-over, and single-blind design study, each participant
completed two separate trials. To determine the acute effect of osmotically stimulated AVP,
measured via copeptin, on glucose regulation, participants received a 120-min saline infusion
followed by a 240-min oral glucose tolerance test (OGTT, Figure 1). Both trials differed only in
saline concentration during the infusion, with each subject receiving 0.1 ml∙kg-1∙min-1 of either
hypertonic saline (HYPER, 3% NaCl), to osmotically stimulate AVP (copeptin) secretion, or
isotonic saline (ISO; 0.9% NaCl), to serve as control (24, 25).

Study controls
Experimental days were separated by one week for males and post-menopausal or
ovariectomized females to ensure sufficient wash-out (26). Female subjects with regular
menstrual cycle were tested during the early follicular phase of two consecutive menstrual
cycles, to control for the effect of reproductive hormones on body fluid balance (27). All subjects
were instructed to consume ample amount of carbohydrates (> 150 g per day) for the three days
leading up to test day to improve the accuracy of the OGTT for glucose tolerance classification
(28). For the 24-h prior to testing subjects recorded all food and fluid intake into a provided food
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diary and refrained from exercise, caffeine, and alcohol. In preparation for the second
experimental day, subjects received a copy of their first pre-trial dietary record and were asked to
replicate it. To standardize the dinner prior to each testing day, subjects consumed a provided
frozen meal (two Smart Ones Spaghetti bowls; 506 kcal, 78 g carbohydrates, 10 g fat, 26 g
protein), before entering a 10-h fasting period prior to the scheduled trial. During this 10-h fast,
subjects were allowed to drink plain water only. Lastly, to ensure adequate hydration, subjects
were instructed to consume provided bottled water based on the 80% of the Institute of Medicine
reference values for water intake (2 L for females and 3 L for males) for the day prior to each
experiment (29). These pre-trial hydration guidelines were based on data from the National
Health and Nutrition Examination Survey, which reports fluid intake to account for
approximately 80% of total water intake (30).

Study protocol
All subjects reported to the lab following a 10-h fast and provided a urine sample.
Hydration status was assessed via urine specific gravity measurement with values <1.020
required to proceed with the protocol (20). Subjects then sat in a comfortable chair and were not
allowed to stand-up or lay down until the end of the experiment to avoid intercompartmental
body fluid shifts associated with changes in body posture (31). An intravenous (IV) catheter was
placed into an antecubital vein and subjects rested for at least 20 min prior to baseline blood
sampling. Following the baseline blood sample collection, saline was infused via an IV pump
(Baxter Flo-Guard® 6201, Baxter Healthcare Corporation, Deerfield, IL, USA) for 120 min, at a
constant rate of 0.1 ml∙kg-1∙min-1. Following the infusion, a blood sample was drawn, and
subjects ingested within five min a 239 mL standardized glucose beverage (Azer Scientific,
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Morgantown, PA, USA) containing 75 g of glucose. Throughout the IV infusion (120 min) and
subsequent OGTT (240 min), blood samples were taken every 30 min for a total of 13 samples.
Blood pressure was recorded right after each blood draw from the non-catheterized arm in
duplicate (Tango+, SunTechMedical Inc, Morrisville, NC, USA). Mean arterial pressure (MAP)
was calculated based on diastolic (DBP) and systolic blood pressure (SBP) with the following
equation: MAP (mmHg) = DBP + [(SBP – DBP) / 3], (32, 33).

Biochemical analysis
At each time point, blood samples were analyzed for POsm (freezing point depression),
electrolyte concentration (ion-sensitive electrodes), total plasma protein (TPP) concentration
(refractometry). Plasma volume changes (∆PV) were calculated based on hematocrit and
hemoglobin concentration with the Dill & Costill equation (34). Copeptin was measured with
random access immunoanalysis (BRAHMS Kryptor Compact Plus, ThermoFisher, Berlin,
Germany). Glucagon, insulin, C-peptide, human corticotropin releasing hormone (CRH),
adrenocorticotropic hormone (ACTH), and cortisol were measured with enzyme-linked
immunosorbent assay. Blood glucose, free fatty acids, and triglycerides were quantified by
spectrophotometry. Aldosterone and plasma renin activity (PRA) were assessed by liquid
chromatography/tandem mass spectrometry, while angiotensin II (AII) concentrations were
determined via radioimmunoassay. Insulin resistance was assessed with the homeostatic model
assessment index (HOMA-IR) at the end of the saline infusion (35), and insulin sensitivity
during the first 120 min of the OGTT test based on the Matsuda index (36).
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Statistical analysis
Data were analyzed via repeated measures analysis of variance to assess within subject
responses across conditions, time, and condition by time. Bonferroni correction was used as posthoc. Baseline data were assessed for normality via the Shapiro-Wilk test. Positive integers for the
area under the curve (AUC) were calculated (37, 38) using MATLAB (MathWorks Inc. 2018,
Natick, MA, USA). All data are reported as means  standard deviation unless otherwise noted.
Statistical significance was set a priori at an alpha of 0.05. Statistical analysis was performed
utilizing the software package JMP® Pro 14.1 (SAS Institute Inc. 2018, Cary, NC, USA).

RESULTS
Hypertonic Saline Infusion
POsm, plasma sodium (PNa), and copeptin at the onset of the infusion (-120 min) did not
differ between trials (P>0.05). During the HYPER trial, POsm, PNa, and copeptin increased and
remained elevated during the entire six-hour protocol (Figure 2, Panel A, B, and D). Plasma
volume was significantly expanded in both trials; however, the expansion was greater during
HYPER compared to the ISO trial (Figure 2, Panel C), despite utilizing the same infusion
volume for both trials (938±183 mL), at a rate of 0.1 ml·kg-1·min-1. Due to plasma volume
expansion in both protocols, measured concentrations were affected. Results with values
corrected for plasma volume expansion are shown in supplemental figures 1 & 2 and in the
supplemental tables 1, 2 & 3. Aldosterone, AII, and PRA were within lower normal
physiological range at the beginning of both protocols and declined following infusion (Table 1).
MAP did not change in response to infusion during the HYPER (pre: 86.2±8.6 mmHg, post:
82.7±7.2 mmHg) or the ISO trial (pre: 84.5±7.9 mmHg, post: 83.3±6.85 mmHg, P>0.05).
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Glycemic Response to Oral Glucose Tolerance Test
Fasting plasma glucose concentrations did not differ between trials (P>0.05) at baseline
(-120 min) and remained unchanged during the 120-min of saline infusion for both trials (Figure
3). The positive integer for the glucose AUC during OGTT (primary outcome) was greater in
HYPER (401.5±190.5 mmol·L-1·min) vs. the ISO trial (354.0±205.8 mmol·L-1·min, P<0.05).
Also, glucose concentration was significantly greater for the HYPER than the ISO trial (P<0.05)
at 60 and 90 min of the OGTT (Figure 3). Baseline serum insulin concentrations did not differ
between conditions (P>0.05) and remained unchanged during the saline infusion. During OGTT
plasma insulin was significantly lower at 30 min for HYPER when compared to the ISO trial
(Figure 3, P<0.05). The positive integer for the insulin AUC during OGTT (primary outcome)
did not differ between trials (HYPER: 55,850±36,488; ISO: 57,205±31,119 pmol·L-1·min,
P>0.05). However, when the positive integer of the AUC was calculated for the first 60 min of
OGTT, it was lower during the HYPER vs. the ISO (11,490±6,659 vs. 15,442±10,295 pmol·L1·min;

P<0.001). C-peptide values did not differ between the two trials during the 120-min of

infusion (P>0.05). During OGTT C-peptide was lower at 30 and 60 min for HYPER trial
(1.06±0.51 and 1.95±0.65 nmol·L-1) compared to the ISO trial (1.41±0.66 and 2.19±0.85
nmol·L-1; P<0.05). The positive integer for the C-peptide AUC during OGTT was smaller in
HYPER (305.1±123.5 nmol·L-1·min) vs. the ISO trial (324.4±120.1 nmol·L-1·min; P<0.05).
HOMA-IR (HYPER: 1.58±0.97, ISO: 1.61±1.09; P>0.05) and the Matsuda index of insulin
sensitivity (HYPER: 9.2±5.2, ISO: 9.0±4.9) did not differ between trials (P>0.05).
Serum glucagon concentration did not differ before saline infusion onset between the two
trials (HYPER: 80.1±17.3, ISO: 79.9±15.7 ng·L-1). However, it decreased significantly as a
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response to the isotonic saline (72.6±14.4 ng·L-1, P<0.05), which was not seen during the
hypertonic infusion (75.0±16.2 ng·L-1). No statistically significant differences for glucagon at
any particular timepoint were observed between the two trials during OGTT (P>0.05). However,
the positive integer for the AUC of glucagon during OGTT was significantly greater in HYPER
(19,303±3,939 ng·L-1·min) vs. the ISO trial (18,600±3,755 ng·L-1·min; P<0.05). Serum free fatty
acids and triglycerides decreased as a response to the 75 g of glucose ingestion during OGTT
(see Supplemental Table 3), however, no statistical difference was observed between two trials
(P>0.05).

Hypothalamic-Pituitary-Adrenal Axis
The HPA axis hormonal responses appear in Table 2. CRH did not change during the
experiment and no statistical difference was observed between trials (P>0.05). ACTH did not
differ between the two trials at any timepoint (P>0.05). Compared to the baseline value, ACTH
was significantly lower at 120-min of OGTT during the HYPER trial and at 0 and 120 min of
OGTT in the ISO trial (P<0.05, Table 2). Cortisol concentrations decreased from baseline
(P<0.05), but no significant differences between the trials were observed (P>0.05, Table 2).

DISCUSSION
The aim of the present study was to examine the acute and independent effect of
osmotically stimulated AVP, measured via surrogate marker copeptin, on glucose regulation in
healthy adults. Our main finding was that the glycemic response during OGTT under the
hypertonic condition was significantly greater compared to the isotonic control. These data
suggest that osmotically stimulated AVP (copeptin) may acutely impair glucose homeostasis.
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The study design was successful in inducing a steady increase in POsm during hypertonic
infusion, and in response, a sustained elevated concentration of AVP, measured via copeptin,
which lasted for the entirety of the 6-h protocol. Furthermore, our experiment attained a
suppression of RAAS as a response to baroreceptor loading due to volume increase in both trials
via saline infusion. Our data showed that subjects started the experiment well hydrated, with
levels of renin, aldosterone, and angiotensin II within the low physiological ranges which were
then further reduced during the saline infusion protocol for both conditions. Hence, we were able
to osmotically stimulate the secretion of AVP while keeping RAAS suppressed, therefore
enabling the assessment of its independent impact on glycemic response during an OGTT.
Copeptin concentrations observed during both trials were comparable to higher physiological
ranges assessed in free-living individuals (6).
The AUCs for both glucose and glucagon, assessed during the 240-min OGTT period,
were significantly greater during the hypertonic trial compared to isotonic control. This builds
upon previous observations by Spruce et al., who infused exogenous vasopressin to yield
moderate and high levels of circulating vasopressin respectively, with the aim to examine its
effects on glucose kinetics via use of tritium-labeled glucose in healthy adults (39). In their
findings, Spruce et al. reported that rates of glucose appearance and glucagon concentration were
significantly increased in response to the moderate vasopressin infusion with no further increases
detected when increasing the AVP infusion load, suggesting a sensitive interlink between
circulating vasopressin concentrations and glucose kinetics. In line, Keller et al. also reported
increased rates of glucose appearance assessed via stable isotope tracer methodology in a similar
experiment employing infusion of hypertonic saline to shrink cell volume (45). Even though
circulating AVP concentrations were not measured by Keller et al., we can infer that the increase
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in plasma osmolality beyond 300 mmol·kg -1 as a response to the 5% saline infusion employed,
would have also yielded an increased stimulation of endogenous AVP secretion.
In contrast, a recent study by Carroll et al. reported no differences in glycemic regulation
assessed via OGTT in acutely hypohydrated adults (40). In this study, subjects underwent two
passive heating trials followed by either fluid replacement (control) or fluid restriction
(hypohydration) to induce the desired testing condition before an OGTT assessment followed the
subsequent day. However, passive heating per se has previously been reported to increase
glucose and insulin concentrations (41). Thus, it is possible that the heat-stress subjects were
exposed to in preparation for both conditions could have interfered with their findings.
Although in the current study the overall AUC for insulin did not differ between
conditions during OGTT, the AUC was lower for HYPER when assessed during the first 60-min
of OGTT. Similar to insulin, C-peptide values were lower during HYPER at 30 and 60 min of
OGTT, with the positive integer AUC for C-peptide also being lower for the HYPER than the
ISO trial. No differences were seen on insulin resistance/sensitivity at the end of saline infusion
nor during the OGTT assessed via HOMA-IR and Matsuda index, respectively. These data are in
contrast with previous studies indicating that elevated copeptin and hyperosmolality were factors
contributing to insulin resistance (16, 26). One possibility for a difference in findings is the
employed infusion model, resulting in hypervolemic hyperosmolality. While in natural occurring
hypovolemic dehydration baroreceptors unloading results in activation of RAAS (18), by design,
our study meant to keep RAAS deactivated. With activity of aldosterone and AII kept low, their
reported interference on glucose uptake at the level of the skeletal muscle may, therefore, also be
minimized (42-44), which could explain the lack of effect seen in Matsuda and HOMA-IR
assessments when comparing hyperosmotic to iso-osmotic conditions.
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Although AVP is well-known for its anti-diuretic and pressor effects, widespread AVP
receptors would suggest a broad range of central and peripheral effects. Specific to metabolic
dysfunction, both V1a and V1b receptors have been implicated in glycemic control and insulin
resistance. V1a receptors have been previously described to increase hepatic glycogenolysis, and
gluconeogenesis in vitro and during animal experiments, thus elevating plasma glucose (10, 11,
45). Moreover, glucagon can induce the stimulation of hepatocytes and increase glycemia, while
AVP can induce glycolysis independently. Lastly, alpha and beta cells of the islets of Langerhans
both inhabit V1b receptors which have been implicated with stimulating both insulin and
glucagon (10, 45-47). Based on these previous findings, it can be hypothesized that in our
experiment, the osmotic stimulation of AVP seen during HYPER could have induced greater
glycemic responses during OGTT, via a two-fold effect: the V1a receptor activation yielding in
direct hepatic release of glucose, along with activation of V1b receptors, resulting in an increase
in circulating glucagon concentrations.
Previous studies in humans have suggested an impaired suppression of glucose
production induced by cortisol infusion (23). Recently, Johnson et al., reported glycemic
impairment following three days of decreased water intake in T2D subjects during an OGTT to
be associated with elevated cortisol (48). AVP also has been shown to stimulate ACTH secretion
directly, in the absence of CRH stimulus, which in turn elevates cortisol secretion (49). However,
in the present study no differences in ACTH, CRH, or cortisol were observed between the trials
showing that the AVP-driven stimulation of the HPA axis might not be an acute but rather a
long-term stress response (50).
During the last decade, epidemiological evidence has shown that low water intake is
associated with higher blood glycemia (9, 51, 52). Interestingly, small interventional trials have
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shown that days or weeks of increased water intake can lower circulating copeptin (53, 54) or
AVP (55). In particular Enhorning et al. examined the glycemic responses of healthy adults
following a one-week increased water intake intervention, and reported that the increased water
intake in low drinkers with high baseline copeptin led to lower fasting glucagon without any
changes in insulin (53). Furthermore, a recent study by Asferg et al. measured higher circulating
concentrations of copeptin and glucagon in obese men than in normal control subjects, with
copeptin showing significant association with glucagon concentrations independent of weight
status (56). Therefore, these data might suggest water intake as a potential intervention strategy
to lower AVP, since elevated glucagon per se has been identified as a risk factor for impaired
glucose tolerance and T2D (53, 57-60).
The present study comes with several limitations. Even though our data did not indicate
non-compliance, preparation of subjects for each OGTT trial relied on written instructions and
self-reported compliance. Secondly, utilization of hypertonic saline causes the “unnatural” state
of hypertonic hypervolemia. With RAAS suppressed, potential interplay with AVP and
synergistic effects on glucose regulation naturally occurring during states of negative water
balance in free living adults cannot be assessed. Also, based on previous data, both cell volume
alterations and vasopressin have been linked to glucose regulatory impairments. Use of the
hypertonic infusion protocol does not render a way to distinguish whether the observed
hyperglycemic effect was driven by cell shrinkage and/or AVP. However, both stimuli co-exist
during naturally occurring states of dehydration. Furthermore, data both in experimental animals
(10, 11) and in humans where exogenous vasopressin infusion was employed indicate that AVP
seems to have a direct effect on hyperglycemia (39). Another limitation of the osmotic
stimulation protocol is that even though the same amount of fluid was infused in both trials, the
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osmotic load of the hypertonic fluid led to greater plasma volume expansion when compared to
the isotonic infusion. The isotonic fluid could move from the vascular to the interstitial space
while the hypertonic fluid could possibly draw fluids from the interstitial and intracellular space
into the vasculature via osmosis. As a result, the greater plasma volume present in the
vasculature could have diluted the concentration of blood measures leading to lower measured
concentrations. However, since systemic receptors are sensing concentration and not total
content, the uncorrected values are presented in the manuscript. The corrected data which take
into account the dilution effect associated with the occurred plasma volume expansion in both
trials, appear online as supplemental figures and tables, presenting a very similar response to the
uncorrected data.
With recent data reporting a positive association between copeptin and glucagon in
healthy obese men (56), our study adds to the literature by showing elevated concentrations of
glucagon in response in the presence of high circulating concentrations of copeptin during the
OGTT. Our findings are novel, as potential noise rendered from the normally occurring interplay
of RAAS was controlled for, therefore allowing for an estimation of impact stemming from the
stimulation of AVP concentration alone on metabolic function.
In summary, the present data indicate acute osmotic stimulation of copeptin, measured as
a surrogate marker of AVP, led to greater hyperglycemic responses during an oral glucose
challenge, potentially associated with greater glucagon response.
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FIGURE LEGENDS
Figure 1
Protocol timeline. Infusion protocol started at -120 min ending at time point 0 min. The oral
glucose tolerance test (OGTT) of 75 g was administered at 0min, sample collection continued
until 240 min.
Figure 2
Mean plots of plasma concentrations during the hypertonic and isotonic conditions for: A –
plasma osmolality (POsm), B – plasma sodium (PNa), C – changes in plasma volume and D –
copeptin. Error bars depict standard error of the mean.
* denotes statistically significant difference between conditions for the same timepoint (P<0.05).
Figure 3
Mean plots for glycemic responses during both conditions for glucose (Panel A) and insulin
(Panel B). Error bars depict standard error of the mean.
* denotes statistically significant difference between conditions for the same timepoint (P<0.05)
.
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TABLE 2.1 Fluid regulatory hormone responses

HYPER

ISO

Time
min

-120

0

240

-120

0

240

Aldosterone
pmol∙L-1

144±96

58±30†

55±28†

145±95

61±33†

70±3†

Angiotensin II
pmol∙L-1

22.0±10.7

16.3±6.5*†

20.8±12.1

23.9±10.8

21.9±9.1

24.0±8.6

Plasma Renin Activity
ng∙mL∙h-1

0.86±0.57

0.43±0.24*
†

0.57±0.49*

0.95±0.50

0.66±0.39†

0.99±0.61
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* significant difference between conditions at given timepoint, † significant difference from baseline of the same trial (-120 min,
P<0.05)

TABLE 2.2 Hypothalamic-pituitary-adrenal axis hormonal response

HYPER

ISO

Time
min

-120

CRH
ng∙L-1

518±388 461±363

0

60

120

240

-120

493±390

505±413

455±338

519±467 484±427

ACTH
pmol∙L- 4.0±2.5 3.6±2.2
3.3±1.8
3.2±1.6† 3.5±2.0
1
Cortisol
nmol∙L- 367±205 259±146† 292±163† 223±118† 292±145†
1
† significant difference from baseline of the same trial (-120 min, P<0.05)

3.8±2.5

0

2.8±1.6†

60

120

240

513±461

509±428

523±437

3.4±2.0

3.0±1.8†

3.8±2.2

410±186 228±130† 248±116† 249±124† 276±146†
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Figure 2.1
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Figure 2.2.
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Figure 2.3.

IV.
CONCLUSIONS
These studies sought to determine whether states of acute elevations in circulating
vasopressin, assessed by copeptin, would impair glucose kinetics following an oral glucose
challenge in healthy adults with no reported history, or laboratory indices of diabetes. In order to
investigate this, we first established a methodology potent in achieving acute increases in
copeptin concentrations, while silencing RAAS affiliated hormones. Infusion with hypertonic
saline achieved an endogenous stimulation of copeptin, which resulted in concentrations within
physiological ranges comparable to those reported in epidemiological studies to present a higher
risk for T2DM. Due to the volume load in both infusion protocol conditions, RAAS hormones
were either kept at the low range baseline concentrations during the isotonic trials, or
concentrations were even further reduced following hypertonic infusion, as a result of intra and
intercellular water entering the extracellular periphery, following the acutely increased osmotic
pressure gradients. With either newly induced high, or maintained from baseline concentrations
of copeptin, we were then able to assess the effect of circulating copeptin concentrations on
glucose metabolism responses following a standardized oral glucose tolerance test. Our data
showed that during states of high copeptin concentrations, more glucose was present in the
circulation compared to states of normal to low copeptin concentrations following an
administration of an identical glucose bolus for both conditions. While insulin responses were
similar for both conditions, the incremental area under the curve for glucagon was significantly
larger during high circulating copeptin concentrations.
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This data suggests that during acute states of high circulating copeptin concentrations,
glucagon is also stimulated, resulting in a heightened glucose appearance in the circulation
presumably from hepatic glucose production. While our findings report measurements taken
during acute states of high copeptin, a recent study found a positive correlation between fasting
glucagon and copeptin concentrations in free living adults, suggesting that these acute findings
are valid in chronic states as well. Furthermore, current knowledge in type 2 diabetes
pathophysiology touts glucagon dysregulation, more specifically, hyperglucagonemia as a
precursor to T2DM onset. While defining the exact mechanisms involved in stimulation of
glucagon via AVP/copeptin is beyond the scope of this study design, future research should seek
to examine the interplay of AVP/copeptin further. Moreover, additional data is needed to outline
efficacy of hydration status management on circulating copeptin concentrations and preserving
long-term health outcomes.
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APPENDIX B
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SUPPLEMENTAL TABLE 2.1. Fluid regulatory hormone responses corrected for plasma volume expansion

HYPER

ISO

Time
min

-120

0

240

-120

0

240

Aldosterone
pmol∙L-1, Corrected

144±96

69±36†

66±29†

145±95

71±35†

81±32†

Angiotensin II
pmol∙L-1, Corrected

22.0±10.7

19.1±8.1

23.3±14.5

23.9±10.8

21.9±9.5

23.5±13.4

Plasma Renin Activity
ng∙mL∙h-1, Corrected

0.86±0.57

0.53±0.34*†

0.62±0.47*†

0.95±0.50

0.72±0.41*†

1.1±0.69*
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* significant difference between conditions at given timepoint, † significant difference from baseline of the same trial (-120 m

SUPPLEMENTAL TABLE 2.2. Hypothalamic-pituitary-adrenal axis hormonal response corrected for plasma volume
expansion

HYPER

ISO
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Time
-120
0
60
120
240
-120
0
60
120
240
min
CRH
ng∙L-1
518±388 544±429 562±439 576±463 502±369
519±467 535±473 555±499 550±467 557±465
Corrected
ACTH
pmol∙L-1
4.0±2.5
4.3±2.7*
4.1±2.0
3.5±1.8
3.9±2.1
3.8±2.5 2.9±1.9†
3.7±2.1
3.4±2.0
4.0±2.3
Corrected
Cortisol
nmol∙L-1 367±205 328±208†* 333±197 269±140† 323±170
410±186 250±144† 275±122† 254±137† 277±160†
Corrected
* significant difference between conditions at given timepoint, † significant difference from baseline of the same trial (-120 min).
P<0.05

SUPPLEMENTAL TABLE 2.3. Fatty Acid Response

HYPER

ISO

Time
-120
0
60
120
240
-120
0
60
120
240
min
Triglyceride
1.25±0.5 1.13±0.4 1.11±0.5 1.03±0.53 1.05±0.5
1.26±0.6 1.16±0.6 1.17±0.6 1.09±0.6 1.13±0.6
s
†
8
9
3
6
9
0
5
6
9
mmol∙L-1
Free Fatty
Acids
190±70 150±40†
60±30†
20±10†
80±60†
180±70
160±50
60±50†
30±30†
90±70†
mg∙L-1
* significant difference between conditions at given timepoint, † significant difference from baseline of the same trial (-120 min).
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FIGURE LEGENDS
Supplemental Figure 2.1.
CONSORT 2010 Flow Diagram. Chart reporting total number of participants involved during
enrollment, allocation and analysis.
Supplemental Figure 2.2.
Mean plots for glycemic responses during both conditions for glucose (Panel A) and insulin
(Panel B) corrected for plasma volume expansion. Error bars depict standard error of the mean.
* denotes statistically significant difference between conditions for the same timepoint (P<0.05).
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Supplemental Figure 2.1.
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Supplemental Figure 2.2.

